We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-4.5%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$285M
AUM Growth
+$116M
Cap. Flow
+$64.1M
Cap. Flow %
22.48%
Top 10 Hldgs %
86.17%
Holding
26
New
10
Increased
5
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$69.6M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$30.2M
3
UAM
Universal American Corp
UAM
+$29.3M
4
AERI
Aerie Pharmaceuticals
AERI
+$10.9M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$6.82M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$94.1M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$7.52M
3
AGRX
Agile Therapeutics
AGRX
+$4.37M
4
TTOO
T2 Biosystems, Inc
TTOO
+$3.62M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 91.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASPX
26
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-75,000
Closed -$7.52M
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q2 2015 Portfolio in Review

As of Q2 2015, Foresite Capital Management II held 26 positions worth $285M, up 69% from $169M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Foresite Capital Management II deployed $64.1M of net new capital in Q2 2015, opening 10 new positions and adding to 5 existing holdings. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 421,347 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $94.1M trimmed.

  • Foresite Capital Management II's largest Q2 2015 buy was Chinook Therapeutics, Inc. Common Stock: 421,347 shares worth $63.9M.
  • Foresite Capital Management II added most to Aerie Pharmaceuticals in Q2 2015, an estimated $10.9M increase.
  • Foresite Capital Management II's biggest Q2 2015 reduction was Larimar Therapeutics, cutting an estimated $94.1M.
  • Foresite Capital Management II fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $7.52M.
  • Foresite Capital Management II's ten largest holdings make up 86% of its $285M portfolio in Q2 2015.
  • Foresite Capital Management II opened 10 new positions and closed 4 in Q2 2015.
  • Foresite Capital Management II's portfolio value rose 69% quarter-over-quarter to $285M.

Based on Foresite Capital Management II's 13F filing for Q2 2015, filed 14 Aug 2015.